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dbstract
Nucleobase containing compounds might constitute a potential alternative to conventional antibiotics in the treatment ofHelicobacter pylori
nfections. N4-alkyloxycarbonyl-cytosine derivatives were synthesized and subjected to basic physicochemical characterisation including
ssessment of hydrolytic stability in various matrices. pH-rate profiles of selected compounds (range 0–12) were constructed. Hydrolysis
f the derivatives in slightly alkaline solution (60 ◦C) resulted in quantitative conversion to parent cytosine whereas at acidic pH (60 ◦C)
iberation of cytosine was in most cases accompanied by the parallel formation of uracil. Interestingly the lipophilicN4-adamantyloxycarbonyl-
ytosine prodrug exhibited a half-life of 41 min (pH 1.1 at 37 ◦C) with quantitative conversion to parent cytosine, the degradation rate being
pproximately 200 times faster than that of the non-cyclic aliphatic derivatives investigated. The presence of pig stomach homogenates, pepsin
and H. pylori did not have a noteworthy catalytic effect on the hydrolysis of the derivatives. The release of parent cytosine was markedly
elayed from alginic acid gels loaded with the acid-labile and poorly soluble ADC prodrug as compared to gels loaded with parent cytosine.
2004 Elsevier B.V. All rights reserved.
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. Introduction
Helicobacter pylori, a spiral bacterium colonizing the gas-
ric mucus, is recognized to be a major cause of gastric ulcer
Abbreviations: MC, N4-methyloxycarbonyl-cytosine; EC, N4-ethyl-
xycarbonyl-cytosine; NBC, N4-n-butyloxycarbonyl-cytosine; IBC, N4-
sobutyloxycarbonyl-cytosine; NC, N4-neopentyloxycarbonyl-cytosine;
C, N4-hexyloxycarbonyl-cytosine; OC, N4-octyloxycarbonyl-cytosine;
DC, N4-adamantyloxycarbonyl-cytosine; BC, N4-benzyloxycarbonyl-
ytosine
∗ Corresponding author. Tel.: +45 3530 6284; fax: +45 3530 6010.
E-mail address: kap@dfuni.dk (K. Petersson).
(Hopkins et al., 1996). To eradicateH. pylori conventional an-
tibiotics are generally used. In light of the fact that pathogenic
bacteria may develop resistance towards conventional antibi-
otics (Perri et al., 2003), nucleobase containing compounds
such as cytosine nucleosides (Isono, 1991) and peptide nu-
cleic acids (Good and Nielsen, 1998) might constitute a po-
tential therapeutic alternative.
Various derivatives of the exocyclic amino group (N4) in
cytosine containing compounds have been prepared and eval-
uated as prodrugs: (i) N-mannich bases (Koch and Sloan,
1987); (ii) amides (Miwa et al., 1990; Choe et al., 2002);
(iii) alkyloxycarbonyl derivatives (Choe et al., 2002) and
928-0987/$ – see front matter © 2004 Elsevier B.V. All rights reserved.
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Fig. 1. Structure of cytosine and the N4-alkyloxycarbonyl-derivatives of cytosine.
(iv) dialkylamino-methylene derivatives (Kerr and Kalman,
1994). Capecitabine is a pentyloxycarbonyl prodrug deriva-
tive where drug release involves deacylation by a car-
boxylesterases (Shimma et al., 2000).
Antibiotics used to eradicate H. pylori are usually admin-
istered in the form of conventional oral dosage forms. The
concentration of the antibiotics at the target site is thus mainly
dependent on drug transport/diffusion from the blood into the
gastric lumen (exsorption). In contrast, transport of an antibi-
otic from the gastric lumen into the mucus through the mucus
layer has been suggested to be more effective in the manage-
ment of such infections (Kimura et al., 1995). Thus, by em-
ploying a delivery system exhibiting prolonged retention and
drug release in the gastric environment the therapeutic value
of the antibiotics might be enhanced. Alginate gel formula-
tions have been shown to provide gastric retention for up to
6 h (Whitehead et al., 1998). The prolonged gastric residence
time of alginate eventually admixed with cationic polymers
like chitosan has been ascribed to mucoadhesive properties
of the polymer systems (Bernkop-Schnurch et al., 2001).
In the present study the nucleobase cytosine has been used
as a model compound for antibiotics containing cytosine sub-
structures. The aim of this study was to characterise synthe-
sized N4-alkyloxycarbonyl derivatives of cytosine (Fig. 1)
with regard to physicochemical properties, chemical stabil-
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(pH 4 and 5), phosphate (pH 3, 6 and 7.4), borate (pH 8.5
and 9.5) and carbonate (pH 11). At pH-values below 2 and
above 12, hydrochloric acid and sodium hydroxide was used,
respectively. A constant ionic strength of the buffer solutions
(µ = 0.5) was maintained by addition of calculated amounts
of potassium chloride.
2.2. General procedure for synthesis of
N4-alkyloxycarbonyl-cytosine derivatives
TheN4-alkyloxycarbonyl derivatives were synthesized ac-
cording to a procedure for synthesis of N4-benzyloxycarbo-
nyl-cytosine (Dueholm et al., 1994) with modifications. The
respective alkyl chloroformate (0.036 mol) was added over a
period of 1 h to a suspension of cytosine (0.018 mol) in dry
pyridine (100 ml) at −10 to 0 ◦C under argon. In case of the
N4-adamantyloxycarbonyl derivative, the fluoroformate was
used. The mixture was allowed to heat to room temperature
and stirred overnight. The suspension was evaporated to dry-
ness in vacuo. Water (20 ml) was added and pH was adjusted
to 1 with 4 M hydrochloric acid. The resulting white precip-
itate was filtered off, washed with water, boiled with abso-
lute ethanol (50–100 ml) for 10 min, cooled to 10 ◦C, filtered,
washed with ether and dried in vacuo over phosphorous(V)-
oxide.
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Dty, and stability in biological matrices. In addition, prelim-
nary data of drug release from alginic acid gels formed in
itu are reported.
. Materials and methods
.1. Materials
Cytosine and N,N-dimethylacetamide (DMA) were pur-
hased from Bie & Berntsen, Copenhagen, Denmark. n-
ctanol was obtained from VWR International, Copenhagen,
enmark. Alkyl haloformates and pyridine were purchased
rom Sigma–Aldrich, Copenhagen, Denmark. Sodium algi-
ate (Protanal LF200DL) was a gift from FMC BioPolymer,
rammen, Norway. Chemicals for preparation of buffers and
PLC mobile phases were of analytical grade. Demineralised
ater was used throughout. The buffers used were acetateThe derivatives were subjected to elemental analysis,
elting points (differential scanning calorimetry), mass spec-
rometry and NMR spectrometry. NMR spectra were ob-
ained at 25 ◦C on a Bruker AMX 400 or Bruker AV 600
pectrometer (proton frequency 400.13 and 600.13 MHz) in
MSO-d6. Chemical shift values (δ) are reported in parts
er million (ppm) relative to tetramethylsilane (TMS) used
s an internal standard. Coupling constants (J) are given in
z, and multiplicities are reported as apparent splittings ab-
reviated as s (singlet), d (doublet), t (triplet), q (quartet), p
pentet), n (nontet), m (multiplet), and br (br). Due to solu-
ility limitations, 13C NMR spectra were not recorded for all
he derivatives.
N4-methyloxycarbonyl-cytosine (MC): 17% yield. Anal.
alcd. (C6H7N3O3): C, 42.61; H, 4.17; N, 24.84. Found: C,
2.57; H, 4.16; N, 24.63. Mp: 270.6 ◦C (275–280 ◦C (Nery,
969)). MS: m/z = 169.9 (MH+). 1H NMR (400.13 MHz,
MSO-d6): δ 3.67 (s, 3H, H-1′); 6.92 (d, J = 7.1 Hz, 1H,
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H-5); 7.77 (d, J = 7.1 Hz, 1H, H-6); 10.66 (br, s, 1H, NH);
11.40 (br, s, 1H, NH). 13C NMR (100.6 MHz, DMSO-d6): δ
52.3 (C-1′); 93.3 (C-5); 146.6 (C-6); 155.7 (C-2); 163.5 (C-4)
NCOO was not observed due to exchange broadening.
N4-ethyloxycarbonyl-cytosine (EC): 92% yield. Anal.
Calcd. (C7H9N3O3): C, 45.90; H, 4.95; N, 22.94. Found: C,
45.73; H, 4.93; N, 22.78. Mp: 280.7 ◦C (302–308 ◦C (Nery,
1969); decompose above 290 ◦C (Vincze et al., 1973)). MS:
m/z = 183.9 (MH+). 1H NMR (400.13 MHz, DMSO-d6): δ
1.22 (t, J = 7.1 Hz, 3H, H-2′); 4.13 (q, J = 7.1 Hz, 2H, H-1′);
6.91 (d, J = 7.1 Hz, 1H, H-5); 7.77 (d, J = 7.1 Hz, 1H, H-6);
10.50 (br, s, 1H, NH); 11.41 (br, s, 1H, NH).
N4-n-butyloxycarbonyl-cytosine (NBC): 41% yield. Anal.
Calcd. (C9H13N3O3): C, 51.18; H, 6.20; N, 19.89. Found: C,
50.93; H, 6.16; N, 19.70. Mp: 297.6 ◦C. MS: m/z = 211.9
(MH+). 1H NMR (400.13 MHz, DMSO-d6): δ 0.90 (t, J =
7.3 Hz, 3H, H-4′); 1.35 (m, 2H, H-3′); 1.58 (m, 2H, H-2′);
4.09 (t, J = 6.7 Hz, 2H, H-1′); 6.89 (d, J = 7.1 Hz, 1H, H-5);
7.76 (d, J = 7.1 Hz, 1H, H-6); 10.48 (br, s, 1H, NH); 11.35
(br, s, 1H, NH).
N4-isobutyloxycarbonyl-cytosine (IBC): 63% yield. Anal.
Calcd. (C9H13N3O3): C, 51.18; H, 6.20; N, 19.89. Found: C,
51.47; H, 6.27; N, 19.72. Mp: 304.6 ◦C. MS: m/z = 211.9
(MH+). 1H NMR (400.13 MHz, DMSO-d6): δ 0.91 (d, J =
6.7 Hz, 6H, H-3′); 1.90 (n, J = 6.7 Hz, 1H, H-2′); 3.88 (d,
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N4-adamantyloxycarbonyl-cytosine (ADC): 23% yield.
Anal. Calcd. (C15H19N3O3): C, 62.27; H, 6.62; N, 14.52.
Found: C, 61.95; H, 6.83; N, 14.20. Mp: 279.8 ◦C. MS: m/z
= 290.0 (MH+). 1H NMR (400.13 MHz, DMSO-d6): δ 1.63
(m, br, 6H); 2.09 (m, br, 6H); 2.15 (m, br, 3H); 6.85 (d, J =
7.1 Hz, 1H, H-5); 7.76 (d, J = 7.1 Hz, 1H, H-6); 10.30 (br,
s, 1H, NH); 11.44 (br, s, 1H, NH). 13C NMR (100.6 MHz,
DMSO-d6): δ 30.1 (C-3′); 35.4 (C-4′); 40.8 (C-2′); 80.5 (C-
1′); 93.4 (C-5); 146.5 (C-6); 155.3 (C-2); 163.4 (C-4) NCOO
was not observed due to exchange broadening.
N4-benzyloxycarbonyl-cytosine (BC): 43% yield. Anal.
Calcd. (C12H11N3O3): C, 58.77; H, 4.52; N, 17.13. Found: C,
58.61; H, 4.49; N, 17.05. Mp: 292.1 ◦C (>250 ◦C (Dueholm
et al., 1994; Thomson et al., 1995)). MS: m/z = 245.9 (MH+).
1H NMR (600.13 MHz, DMSO-d6): δ 5.17 (s, 2H, H-1′);
6.92 (d, J = 7.1 Hz, 1H, H-5); 7.34 (m, 1H, H-5′); 7.40 (m,
4H, H-3′ and H-4′); 7.79 (d, J = 7.1 Hz, 1H, H-6); 10.81 (br,
s, 1H, NH); 11.33 (br, s, 1H, NH). 13C NMR (150.9 MHz,
DMSO-d6): δ 66.4 (C-1′); 93.5 (C-5); 127.8 (C-3′); 128.1 (C-
5′); 128.4 (C-4′); 136.0 (C-2′); 146.6 (C-6); 153.4 (NCOO);
155.7 (C-2); 163.6 (C-4). The spectral data are consistent
with those reported earlier (Thomson et al., 1995).
2.3. Determination of aqueous solubility and partition
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p= 6.7 Hz, 2H, H-1 ); 6.89 (d, J = 7.1 Hz, 1H, H-5); 7.77
d, J = 7.1 Hz, 1H, H-6); 10.95 (br, s, 2H, NH). 13C NMR
100.6 MHz, DMSO-d6): δ 18.6 (C-3′); 27.3 (C-2′); 70.7 (C-
′); 93.4 (C-5); 146.5 (C-6); 153.7 (NCOO); 155.7 (C-2);
63.6 (C-4).
N4-neopentyloxycarbonyl-cytosine (NC): 69% yield.
nal. Calcd. (C10H15N3O3): C, 53.32; H, 6.71; N, 18.66.
ound: C, 53.29; H, 6.74; N, 18.56. Mp: 309.6 ◦C. MS: m/z
225.9 (MH+). 1H NMR (400.13 MHz, DMSO-d6): δ 0.92
s, 9H, H-3′); 3.79 (s, 2H, H-1′); 6.89 (d, J = 7.1 Hz, 1H, H-
); 7.77 (d, J = 7.1 Hz, 1H, H-6); 10.95 (br, s, 2H, NH). 13C
MR (100.6 MHz, DMSO-d6): δ 26.0 (C-3′); 31.2 (C-2′);
3.8 (C-1′); 93.4 (C-5); 146.6 (C-6); 153.7 (NCOO); 155.7
C-2); 163.6 (C-4).
N4-hexyloxycarbonyl-cytosine (HC): 55% yield. Anal.
alcd. (C11H17N3O3): C, 55.22; H, 7.16; N, 17.56. Found: C,
5.28; H, 7.23; N, 17.43. Mp: 292.2 ◦C (285–288 ◦C (Nery,
969)). MS: m/z = 239.9 (MH+). 1H NMR (400.13 MHz,
MSO-d6): δ 0.87 (t, J = 7.0 Hz, 3H, H-6′); 1.23–1.37 (m,
H, H-3′, H-4′, H-5′); 1.59 (p, J = 6.7 Hz, 2H, H-2′); 4.08 (t,
= 6.7 Hz, 2H, H-1′); 6.89 (d, J = 7.1 Hz, 1H, H-5); 7.76 (d,
= 7.1 Hz, 1H, H-6); 10.48 (br, s, 1H, NH); 11.38 (br, s, 1H,
H).
N4-octyloxycarbonyl-cytosine (OC): 72% yield. Anal.
alcd. (C13H21N3O3): C, 58.41; H, 7.92; N, 15.72. Found:
, 58.34; H, 7.93; N, 15.62. Mp: 294.0 ◦C. MS: m/z = 268.0
MH+). 1H NMR (400.13 MHz, DMSO-d6): δ 0.86 (t, J =
.9 Hz, 3H, H-8′); 1.21-1.37 (m, 10H, H-3′, H-4′, H-5′, H-6′,
-7′); 1.59 (p, J = 6.7 Hz, 2H, H-2′); 3.79 (t, J = 6.7 Hz, 2H,
-1′); 6.87 (br, s, 1H, H-5); 7.76 (d, J = 7.1 Hz, 1H, H-6);
0.48 (br, s, 1H, NH); 11.37 (br, s, 1 H, NH).Excess amounts of the test compounds were suspended
n buffer solution (5–10 ml) in screw-capped test tubes. The
ubes were sonicated (30 min) followed by agitation at 37 ±
.5◦C in an incubator hood until equilibrium was attained
4–24 h). The supernatant was filtered through a 0.45m
embrane filter discarding the first 3–5 ml. The filtrate was
iluted prior to HPLC analysis. The filtration process was car-
ied out in the incubator hood and the equipments used were
ll preheated to 37 ◦C. The partition of the test compounds
etween n-octanol and buffer solutions was determined at 37
0.5 ◦C. The phases were mutually saturated before use. The
artition coefficient was calculated from the concentration of
he test compound in the aqueous phase before and after at-
ained equilibrium (6–24 h) measured by HPLC. Solubilities
nd partition coefficients were calculated from experiments
one in triplicate.
.4. Stability measurements in aqueous solutions
The reactions were initiated by adding 100–500l of a
tock solution of the test compounds in methanol to 10.0 ml
f preheated buffer solution in screw-capped test tubes re-
ulting in a final concentration of 0.6–10M. The reaction
olutions were kept at constant temperature in a water bath
nd at appropriate time intervals samples were taken and anal-
sed by HPLC. In order to, respectively, stop fast proceeding
eactions and neutralise acidic samples prior to product anal-
ses, these samples were mixed with an equal volume of 1 M
hosphate buffer pH 7.4.
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2.5. Stability measurements in biological media
A stock homogenate (50% (w/v)) of pig stomach mu-
cus was prepared in ice cold 0.02 M phosphate buffer pH
7.40. A stock solution of pepsin A (7500 U/ml) was prepared
in 0.02 M acetate buffer pH 4.4 (Rajagopalan et al., 1966).
The final homogenates (10% (w/v)) and enzyme solutions
(750 U/ml) were prepared by dilution with 0.01 M hydrochlo-
ric acid. Pepsin A was stable in the final solutions for 24 h
based on studies using haemoglobin as reference substrate
(Anson, 1938). H. pylori ATCC 700392 were dispersed in
0.9% (w/v) NaCl at a concentration of 108 cells/ml (estimated
using OD measurement at 600 nm). A part of this suspension
was sonicated for 10 min to disturb cell membranes and re-
lease intracellular enzymes. The preheated media were spiked
with the individual test compound (2–10M) and kept at 37
± 0.5 ◦C. At appropriate time intervals two aliquots were
withdrawn and added to one aliquot of a 6% (w/v) perchloric
acid solution in order to deproteinize the samples. In case of
ADC one aliquot were added to two aliquots of 97% (v/v)
methanol in 1 M aqueous sodium hydroxide. After mixing
and centrifugation for 15 min at 13000 rpm, the supernatant
was analysed by HPLC.
2.6. Preparation of alginate formulations
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2.8. HPLC analysis
HPLC analyses were performed with a Shimadzu LC-6A,
Merck Hitachi L-6000 or Merck Hitachi L-7100 pump and a
Merck Hitachi L-7480, Jasco 821-FP or Merck Hitachi F1000
FL-detector operating at Ex 288 nm/Em 350 nm when detect-
ing the derivatives and a Merck Hitachi D-4000 UV-detector
operating at 266 nm for detection of degradation products.
Reversed phase chromatography was carried out using a Phe-
nomenex Aqua C18 column (150 mm × 4.6 mm i.d.; 5m
particles) equipped with a C18 precolumn (4 mm × 3.0 mm
i.d.) (Supware, Copenhagen, Denmark). The flow rate was
set at 1 ml min−1. Mobile phase systems of 10–80% (v/v)
methanol in 0.1% (v/v) phosphoric acid were used with the
methanol content adjusted for each compound to provide re-
tention times in the range of 3–8 min. To detect degradation
products and cytosine 0.02 M phosphate buffer pH 7.4 was
used as mobile phase.
3. Results and discussion
3.1. Physicochemical characterisation
The pKa-values of parent cytosine are pKa1 4.6 and pKa2
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tSodium alginate was suspended in DMA solutions of ADC
nd cytosine, respectively. By addition of water under stir-
ing, dissolution of sodium alginate was accompanied by
recipitation of the test compound in case of ADC, whereas
ytosine remained dissolved. The precipitated ADC prodrug
as uniformly distributed throughout the viscous suspension.
rapped air was removed prior to use. The formulations con-
isted of 1% (w/v) aqueous sodium alginate solution contain-
ng 20% (v/v) DMA.
.7. In vitro release from alginate formulations
Release of the compounds from the alginate formulations
as examined using the paddle method (Eur. Ph. 4th disso-
ution test apparatus) at 37 ± 0.5 ◦C according to previous
tudies (Katayama et al., 1999) with modifications. The re-
ease medium (500 ml; 0.1 M HCl pH 1.1) was placed in the
essel and preheated to 37 ± 0.5 ◦C. The liquid formulation
36 ml comprising 18mol of the test compound) was placed
n a Petri dish (6.9 cm × 1.2 cm). A piece of woven gauze
ade from stainless steel wire 0.30 mm in diameter and hav-
ng mesh apertures of 1.00 mm was placed on top of the Petri
ish. The Petri dish was then located at the base of the dis-
olution vessel and stirring of the dissolution medium was
tarted (50 rpm). At appropriate time intervals samples were
ithdrawn, mixed with an equal volume of 1 M phosphate
uffer pH 7.4 and analysed by HPLC. The samples were re-
laced with fresh release medium. Release experiments were
erformed in triplicate.2.2 (Shugar and Fox, 1952) for the protonation at N3 and
eprotonation at N1, respectively. Thus cytosine is positively
harged, neutral and negatively charged under acidic, neutral
nd basic conditions, respectively. The pH-solubility profile
f EC (Fig. 2) reveals enhanced solubility at low and high pH,
espectively. The pKa1-value for EC was calculated (Table 1)
ccording to the method previously described for a weak base
Yalkowsky, 1999).
s = C0(1+ 10pKa−pH) (1)
ig. 2. The pH-solubility profile for EC at 37± 0.5 ◦C andµ = 0.5.Cs refers
o the total pH-dependent solubility (M). Each value is the mean ± S.E.M.
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Table 1
The values of log P, solubility and pKa for cytosine and the N4-
alkyloxycarbonyl-cytosine derivatives at 37 ± 0.5 ◦C
Compound logP Solubility (M) (RSD (%))
Cs,pH 1.1 Cs,pH 7.4 pKa
Cytosine −1.5 (3) n.d. 102624 (4)a 4.6b
MC −0.55 (2) n.d. 1843 (0.3) n.d.
EC −0.085 (2) 2377 (3)c 199 (9) 1.9d
NBC 1.1 (2) 983 (3) 147 (2) 1.9
IBC 1.1 (1) 1670 (3) 235 (2) 1.9
NC 1.5 (1) 886 (3) 122 (2) 1.9
HC 2.3 (4) 34 (4) 4 (2) 1.9
OC 3.3 (10) 0.7 (11) 0.3 (16) 1.9
ADC 2.9 (1) n.d. 19 (9) n.d.
BC 1.3 (2) n.d. 51 (2) n.d.
Experiments performed in triplicate; n.d. = not determined.
a In H2O.
b From Shugar and Fox, 1952.
c At pH 1.0.
d From solubility and partition experiments.
where C0 is the intrinsic solubility determined at least two
pH-units above pKa1 and Cs is the total pH dependent
solubility. Similarly, pKa1-values for the other non-cyclic
derivatives were estimated using the solubility at pH 1.1
and pH 7.4 (Table 1). The pKa1-value is lowered approxi-
mately 2.7 units by the introduction of the alkyloxycarbonyl
group whereas it seems to be unaffected by the chemical
structure of the alkyl substituent (Table 1). These observa-
tions are in favourable agreement with the behaviour of N-
alkyloxycarbonyl derivatives of imidazole-containing com-
pounds (Buur and Bundgaard, 1991; Nielsen et al., 1994) and
N6-alkyloxycarbonyl derivatives of adenine (Giner-Sorolla
and Bendich, 1958). Compared to cytosine, EC possesses an
additional ionisation constant (pKa2) for the leaving of the
proton at N4 which can be calculated to 9.8 using solubil-
ity data and the equation for a divalent acid (Yalkowsky,
1999). Similar observations have been reported for N6-
alkyloxycarbonyl derivatives of adenine (Giner-Sorolla and
Bendich, 1958). The lowered intrinsic solubility of the deriva-
tives relative to parent cytosine (50- to 105-fold) can most
likely be ascribed to an increasing crystal lattice energy,
achieved by enhanced intermolecular attractive interactions
by introduction of the alkyloxycarbonyl-groups. SimilarlyN-
alkyloxycarbonyl derivatives of mitomycin C (Mukai et al.,
1985) exhibited decreased solubility relative to the parent
d
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Fig. 3. The pH-rate profile for the hydrolysis of EC () and ADC prodrug
(X) at 60 ± 0.5 ◦C and µ = 0.5. The solid lines have been calculated from
Eqs. (2) and (3), respectively. The value, kobs refers to the observed pseudo-
first-order rate constant (min−1).
determined at pH 1.5 and the partition coefficient determined
at pH 7.4 (37 ± 0.5 ◦C) and agreed well with those obtained
from solubility data (Table 1).
3.2. Stability measurements in aqueous solutions
To investigate the kinetics of hydrolysis the pH-rate pro-
files of EC and ADC (60± 0.5 ◦C) were established (Fig. 3).
Under constant pH, ionic strength and temperature the degra-
dation reactions displayed first-order kinetics for several
half-lives. Pseudo-first-order rate constants were determined
from the slopes of linear plots of the logarithm of in-
tactN4-alkyloxycarbonyl-cytosine against time. From kinetic
runs with EC employing buffer concentrations in the range
0.02–0.1 M (µ = 0.5) it was observed that the decomposi-
tion rates were not subject to significant general acid–base
catalysis. The shape of the pH-rate profile for EC suggests
that the overall hydrolysis can be accounted for in terms of
spontaneous degradation of the cationic, neutral and anionic
species as described by:
kobs = k01 [aH+ ]
2
[aH+ ]2 + [aH+ ]Ka1 +Ka1Ka2
[aH+ ]Ka1
w
a
trug.
The partition of the test compounds between n-octanol
nd 0.02 M phosphate buffer pH 7.4 were determined at 37
0.5 ◦C. The hydrophobic substituent constant (π = 0.56)
etermined from the slope of the straight line correlation (R2
0.996) between logP and the number of C-atoms in the alkyl
hain for the non-cyclic aliphatic derivatives is in excellent
greement with earlier findings (Hansch and Leo, 1979). The
og P-values for ADC and BC are given in Table 1. Using the
xpression previously given (Larsen et al., 2000) the pKa1-
alue for EC was calculated from the distribution coefficient+ k02 [aH+ ]2 + [aH+ ]Ka1 +Ka1Ka2
+ k03 Ka1Ka2[aH+ ]2 + [aH+ ]Ka1 +Ka1Ka2
(2)
here [aH+ ] is the hydrogen ion activity, and Ka1 and Ka2
re the ionisation constants for the equilibrium between
he cationic and neutral, and neutral and anionic species,
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Table 2
Half-lives, ratio of degradation products and pseudo-first-order rate constants associated the formation of degradation products by hydrolysis of the N4-
alkyloxycarbonyl-cytosine derivatives at 60 ± 0.5 ◦C and µ = 0.5
Compound Half-life (min) (RSD (%)) C/Ua Rate constants (×103 min−1) at pH 1.2
pH 1.2 pH 9.5 kC kU
MC 689 (1) 210 (0.4) 39/64 0.39 0.64
EC 589 (2)b 216 (1)b 20/80 0.24b 0.94b
ECc 6480 (1)b n.d. 20/80 0.02b 0.09b
NBC 624 (2) 388 (0.3) 13/92 0.14 1.02
IBC 619 (1) 412 (2) 14/88 0.16 0.99
NC 617 (1) 492 (5) 78/24 0.88 0.27
HC 590 (5) 423 (1) n.d. n.d. n.d.
OC 625 (2) 510 (2) n.d. n.d. n.d.
ADC 3 (7) 475 (0.3) 96/0 238 0
ADCc 41 (3) n.d. 100/0 16.7 0
BC 350 (2) 211 (0.5) 55/47 1.09 0.93
Experiments performed in triplicate; n.d. = not determined.
a %cytosine/%uracil formed after 8 half-lives at pH 1.2.
b At pH 1.0.
c At 37 ◦C.
respectively. Similarly, the hydrolysis of ADC can be de-
scribed by:
kobs = k01 [aH+ ][aH+ ]+Ka1
+ k02 Ka1[aH+ ]+Ka1
(3)
In Fig. 3 the solid curves drawn were constructed from Eqs.
(2) and (3), respectively. From computer fitting magnitudes
of the pseudo-first-order rate constants k01, k02 and k03 for
EC of 1.37, 0.0145 and 6.33 × 10−3 min−1, respectively,
were calculated and pKa1 and pKa2 estimated to 1.7 and 9.3,
respectively. The corresponding k01 and k02 values for ADC
were 259 and 1.36× 10−3 min−1, respectively and pKa1 were
2.6. The observed agreement between the fitted curve and
experimental data points indicates that Eqs. (2) and (3) ade-
quately describe the degradation kinetics for EC and ADC,
respectively. The shape of the pH-rate profile of EC is com-
parable to those previously reported for N-alkyloxycarbonyl
derivatives of imidazoles (Buur and Bundgaard, 1991) and
benzimidazoles (Nielsen et al., 1994) and benzamide (Kahns
and Bundgaard, 1991).
To extend the study of the hydrolysis, the degradation of
all the derivatives was studied under acidic and basic condi-
tions (pH 1.2 and 9.5, respectively). At pH 9.5 the decom-
positions resulted in quantitative conversion to parent cyto-
sine whereas at pH 1.2 liberation of cytosine was in most
c
l
t
(
i
u
i
N
w
i
B
used in agreement with earlier findings (Garrett and Tsau,
1972). The pseudo-first-order rate constants, kC and kU for
the release of cytosine and uracil from the derivatives at pH
1.2 were calculated from:
kC =
[C]∞kobs,pH1.2
[RC]0
(4)
kU =
[U]∞kobs,pH1.2
[RC]0
(5)
where [RC]0 is the initial concentration of the derivative in-
vestigated and [C]∞ and [U]∞ are the concentrations of cy-
tosine and uracil after 8 half-lives, respectively. Although
exhibiting fairly identical overall chemical stability at pH 1.2
(60 ± 0.5 ◦C) the non-cyclic aliphatic derivatives degrade
to cytosine and uracil in different ratios dependent on the
alkyl chain structure (Table 2). To this end the hydrolysis
of N-alkyloxycarbonyl benzamides at pH > 7 resulted in the
formation of benzoic acid and benzamide favouring the for-
mation of benzoic acid the longer the alkyl chain (Kahns
and Bundgaard, 1991). The slow deamination of cytosine to
uracil has been reported to involve H3O+ attack at C4 fol-
lowed by leaving of NH4+ (pH 1.1; 70 ◦C) (Garrett and Tsau,
1972). Under the assumption that the degradation of the N4-
alkyloxycarbonyl derivatives to uracil follows an analogous
p +
N
c
N
i
d
e
t
1
tases accompanied by the formation of uracil. After 8 half-
ives the sum of the two degradation products were close to
hose of the initial concentrations of test compound (±5%)
Table 2). Identification of the degradation products formed
n acidic and basic media were done by HPLC. The findings
nder acidic conditions were supported by experiments done
n 0.1 M deuterium chloride (60± 0.5 ◦C) determined by 1H
MR for ADC and EC. Comparable cytosine to uracil ratios
as found after 2 and 8 half-lives for MC (pH 1.2) suggest-
ng that the two products were formed by parallel reactions.
oth cytosine and uracil were stable under the conditionsathway with the leaving of NH3 COOR, it is noted that
H3+COOR is a better leaving group than NH4+, which
an be ascribed to the electron withdrawing properties of
COOR. Similar electronic effects have been reported for
4
-methylsubstituted cytidines (Kusmierek et al., 1989). The
nfluence of the temperature (range 37–60 ◦C) on the degra-
ation rate of EC was studied at pH 1.0 and the activation
nergy (Ea) from Arrhenius plot was 90 kJ mol−1 allowing
he half-life of EC at 37± 0.5 ◦C (pH 1.0) to be estimated to
08 h. Interestingly, hydrolysis of ADC resulted in quantita-
ive release of cytosine under acidic conditions at 60± 0.5 ◦C
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Fig. 4. Time course for the degradation of ADC prodrug (X) and formation
of cytosine () at pH 1.1 at 37± 0.5 ◦C and µ = 0.5. Each value is the mean
± S.E.M. of three determinations.
(Table 2) and 37 ± 0.5 ◦C (Fig. 4) exhibiting half-lives of 3
and 41 min, respectively. Thus, under acidic conditions ADC
is approximately 200 times more hydrolytic labile than the
non-cyclic aliphatic derivatives. Although strain often decel-
erates hydrolysis of bridgehead systems, hyperconjugation
often has the opposite effect. Thus a carbocation at C1 in
adamantyl will be stabilised by hyperconjugative electron
donation from C3 and the other identical carbons (Lowry and
Richardson, 1987). Thus, the hydrolysis of ADC may be ex-
pected to proceed via an unimolecular reaction (E1) involving
the formation of the 1-adamantyl carbocation intermediate,
in contrast to the bimolecular reaction (AAC2) involving the
tetrahedral intermediate formed from a nucleophile attack by
a water molecule in case of the non-cyclic aliphatic deriva-
tives (March, 1992).
3.3. Stability measurements in biological media
Estimated half-lives from experiments run for 24 h (37 ±
0.5 ◦C) in the presence of pepsin A (pH 2.2) and mucus ho-
mogenate (pH 3.3) for NBC were 19 and 30 h, respectively.
The correspondent stabilities of IBC were 50 and 69 h, re-
spectively, indicating that NBC and IBC are subject to enzy-
matic hydrolysis by pepsin A. The degradation of the other
derivatives was not significantly affected in the presence of
t
b
b
h
e
(
a
m
p
b
Fig. 5. Release of ADC (X) and cytosine formed by hydrolysis of ADC (©)
from alginic acid gels loaded with the acid-labile and poorly water-soluble
ADC prodrug derivative. For comparison the release of cytosine form similar
gels loaded with equimolar amounts of parent cytosine (). Each value is
the mean ± S.E.M.
3.4. In vitro release from alginate formulations
The obtained stability data indicates that ADC may
be of interest in prodrug design of cytosine containing
antibacterial compounds in relation to stomach specific
delivery. In order to prolong gastric retention of ADC the
prodrug was incorporated into an alginate formulation.
Preliminary studies of the release from alginate formulations
containing cytosine and ADC prodrug, respectively, were
conducted in 0.1 M HCl at 37 ± 0.5 ◦C. Immersing the
alginate formulation into the acidic release medium resulted
in the formation of alginic acid gel structures. In Fig. 5 the
release profile of cytosine and ADC from gels loaded with
ADC prodrug are shown. It is seen that parent cytosine is the
main compound released while only minute amounts of ADC
appears in the release media. For comparison the release
of cytosine from a similar alginate formulation loaded with
equimolar amounts of parent cytosine is also depicted
in Fig. 5. It is apparent that release of parent cytosine is
markedly delayed by employment of the acid-labile and
poorly-soluble adamantyl prodrug derivative with the time
of 50% released being 1.5 h and 4.5 h from cytosine and
ADC loaded gels, respectively. The minute amounts of ADC
present in the release medium show that the formation of
cytosine by hydrolysis of ADC predominantly takes place
i
l
p
t
S
a
c
ahese media. The presence ofH.pyloridid not affected the sta-
ility of any of the derivatives, even though the alkyloxycar-
onyl bond in pentyloxycarbonyl-5′-deoxy-5-fluorocytidine
as been shown to be cleaved by carboxylesterases (Miwa
t al., 1998), enzymes that also are expressed in H. pylori
Mendz et al., 1993). The data may suggest that the N4-
lkyloxycarbonyl derivatives, except ADC, are stable in the
ilieu residing in the stomach and that regeneration of the
arent drug has to rely on cleavage of the alkyloxycarbonyl
ond effected by intracellular bacterial enzymes.nside the gel. The retarded release of cytosine from ADC
oaded gels may be ascribed to the low solubility of the ADC
rodrug and subsequently minor concentration gradient from
he gels to release media as compared to cytosine loaded gels.
ince parent compound is released from the formulation
chievement of a therapeutic effect requires that the parent
ytosine compound is capable of reaching the intended site of
ction.
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4. Conclusion
The synthesized N4-alkyloxycarbonyl-cytosine deriva-
tives exhibited increased lipophilicity, in a predictive manner
(π = 0.56), and lowered intrinsic aqueous solubility, relative
to parent cytosine. The degree of ionisation in acidic me-
dia is markedly suppressed due to the decrease in pKa1 of the
derivatives. The hydrolysis under alkaline conditions resulted
in quantitative conversion to parent cytosine whereas at acidic
pH the liberation of cytosine was in most cases accompanied
by parallel formation of uracil. The lipophilic and poorly
water-soluble ADC prodrug exhibited a hydrolytic half-life
of 41 min at pH 1.1 (37 ◦C) with quantitative conversion to
parent cytosine, the degradation rate being approximately 200
times faster than that of the non-cyclic aliphatic derivatives.
The time of 50% cytosine released from gels loaded with
ADC prodrug at acidic pH was 4.5 h compared to that of
1.5 h from gels loaded with parent cytosine. A study of var-
ious combined formulations based on N4-alkyloxycarbonyl
derivatives of cytosine and alginate based in situ gelling sys-
tems are to be published elsewhere.
Acknowledgements
f
m
e
o
R
A
B
B
C
D
G
G
G
H
Hopkins, R.J., Girardi, L.S., Turney, E.A., 1996. Relationship between
Helicobacter pylori eradication and reduced dudenal and gastric ulcer
recurrence: a review. Gastroenterology 110, 1244–1252.
Isono, K., 1991. Current progress on nucleoside antibiotics. Pharmacol.
Ther. 52, 269–286.
Kahns, A.H., Bundgaard, H., 1991. N-Acyl derivatives as prodrug forms
for amides: chemical stability and enzymatic hydrolysis of various
N-acyl and N-alkoxycarbonyl amide derivatives. Int. J. Pharm. 71,
31–43.
Katayama, H., Nishimura, T., Ochi, S., Tsuruta, Y., Yamazaki, Y., Shibata,
K., Yoshitomi, H., 1999. Sustained release liquid preparation using
sodium alginate for eradication of Helicobacter pyroli. Biol. Pharm.
Bull. 22, 55–60.
Kerr, S.G., Kalman, T.I., 1994. N4-(dialkylamino)methylene derivatives
of 2′-deoxycytidine and arabinocytidine: physicochemical studies for
potential prodrug applications. J. Pharm. Sci. 83, 582–586.
Kimura, K., Ido, K., Saifuku, K., Taniguchi, Y., Kihira, K., Satoh, K.,
Takimoto, T., Yoshida, Y., 1995. A 1-h topical therapy for the treat-
ment of Helicobacter pylori infection. Am. J. Gastroenterol. 90,
60–63.
Koch, S.A., Sloan, K.B., 1987. N-Mannich-base prodrugs of 5-iodo-2′-
deoxycytidine as topical delivery enhancers. Pharm. Res. 4, 317–
320.
Kusmierek, J., Ka¨ppi, R., Neuvonen, K., Shugar, D., Lo¨nnberg, H., 1989.
Kinetics and mechanisms of hydrolytic reactions of methylated cy-
tidines under acidic and neutral conditions. Acta Chem. Scand. 43,
196–202.
Larsen, D.H., Fredholt, K., Larsen, C., 2000. Assessment of rate of drug
release from oil vehicle using a rotating dialysis cell. Eur. J. Pharm.
Sci. 11, 223–229.
L
M
M
M
M
M
N
N
P
R
SWe would like to thank Professor Steen Honore´ Hansen
or carrying out the mass spectrometry analyses. NMR equip-
ent used in this work was purchased via grants from Apotek-
rfonden af 1991, Copenhagen, and The Danish University
f Pharmaceutical Sciences.
eferences
nson, M.L., 1938. The estimation of pepsin, trypsin, papain, and cathep-
sin with hemoglobin. J. Gen. Physiol. 22, 79–89.
ernkop-Schnurch, A., Kast, C.E., Richter, M.F., 2001. Improvement in
the mucoadhesive properties of alginate by the covalent attachment
of cysteine. J. Control. Release 71, 277–285.
uur, A., Bundgaard, H., 1991. Prodrugs of cimetidine with increased
lipophilicity: N-acyloxymethyl and N-alkoxycarbonyl derivatives. Acta
Pharm. Nord. 3, 51–56.
hoe, Y.H., Conover, C.D., Wu, D., Royzen, M., Gervacio, Y., Borowski,
V., Mehlig, M., Greenwald, R.B., 2002. Anticancer drug delivery sys-
tems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C.
II. Efficacy in ascites and solid tumors. J. Control. Release 79, 55–70.
ueholm, K.L., Egholm, M., Behrens, C., Christensen, L., Hansen, H.F.,
Vulpius, T., Petersen, K.H., Berg, R.H., Nielsen, P.E., Buchardt, O.,
1994. Synthesis of peptide nucleic acid monomers containing the four
natural nucleobases: thymine, cytosine, adenine, and guanine and their
oligomerization. J. Org. Chem. 59, 5767–5773.
arrett, E.R., Tsau, J., 1972. Solvolyses of cytosine and cytidine. J.
Pharm. Sci. 61, 1052–1061.
iner-Sorolla, A., Bendich, A., 1958. Synthesis and properties of some
6-substituted purines. J. Amer. Chem. Soc. 80, 3932–3937.
ood, L., Nielsen, P.E., 1998. Inhibition of translation and bacterial
growth by peptide nucleic acid targeted to ribosomal RNA. Proc.
Natl. Acad. Sci. USA 95, 2073–2076.
ansch, C., Leo, A., 1979. Substituent Constants for Correlation Analysis
in Chemistry and Biology. Wiley, New York.owry, T.H., Richardson, K.S., 1987. Influence of solvent, nucleophile,
leaving group, and substrate structure. In: Mechanism and Theory in
Organic Chemistry. Harper & Row, New York.
arch, J., 1992. Advanced Organic Chemistry: Reactions, Mechanisms,
and Structure. John Wiley & Sons, New York.
endz, G.L., Lim, T.N., Hazell, S.L., 1993. Fluorinated probes to mea-
sure carboxylesterase activities using 19F NMR spectroscopy: applica-
tion to erythrocytes and Helicobacter pylori. Arch. Biochem. Biophys.
305, 252–260.
iwa, M., Ishikawa, T., Eda, H., Ryu, M., Fujimoto, K., Ninomiya,
Y., Umeda, I., Yokose, K., Ishitsuka, H., 1990. Comparative studies
on the antitumor and immunosuppressive effects of the new fluo-
rouracil derivative N(4)-trimethoxybenzoyl-5′-deoxy-5-fluorocytidine
and its parent drug 5′-deoxy-5-fluorouridine. Chem. Pharm. Bull. 38,
998–1003.
iwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K.,
Shimma, N., Umeda, I., Ishitsuka, H., 1998. Design of a novel oral flu-
oropyrimidine carbamate, capecitabine, which generates 5-fluorouracil
selectively in tumours by enzymes concentrated in human liver and
cancer tissue. Eur. J. Cancer. 34, 1274–1281.
ukai, E., Arase, K., Hashida, M., Sezaki, H., 1985. Enhanced delivery
of mitomycin C prodrugs through the skin. Int. J. Pharm. 25, 95–103.
ery, R., 1969. Acylation of cytosine by ethyl N-hydroxycarbamate and
its acyl derivatives and the binding of these agents to nucleic acids
and proteins. J. Chem. Soc. (C), pp. 1860–1865.
ielsen, L.S., Slok, F., Bundgaard, H., 1994. N-alkoxycarbonyl prodrugs
of mebendazole with increased water solubility. Int. J. Pharm. 102,
231–239.
erri, F., Qasim, A., Marras, L., O’Morain, C., 2003. Treatment of Heli-
cobacter pylori infection. Helicobacter 8 Suppl. (1), 53–60.
ajagopalan, T.G., Moorre, S., Stein, W.H., 1966. Pepsin from pepsino-
gen: preparation and properties. J. Biological Chem. 241, 4940–4950.
himma, N., Umeda, I., Arasaki, M., Murasaki, C., Masubuchi, K., Ko-
hchi, Y., Miwa, M., Ura, M., Sawada, N., Tahara, H., Kuruma, I.,
Horii, I., Ishitsuka, H., 2000. The design and synthesis of a new tumor-
selective fluoropyrimidine carbamate. Capecitabine. Bioorg. Med.
Chem. 8, 1697–1706.
K. Petersson et al. / European Journal of Pharmaceutical Sciences 23 (2004) 337–345 345
Shugar, D., Fox, J.J., 1952. Spectrophotometric studies op nucleic acid
derivatives and related compounds as a function of pH. Biochimica
et Biophysica Acta 9, 199–218.
Thomson, S.A., Josey, J.A., Cadilla, R., Gaul, M.D., Hassman, C.F.,
Luzzio, M.J., Pipe, A.J., Reed, K.L., Ricca, D.J., Wiethe, R.W., No-
ble, S.A., 1995. Fmoc mediated synthesis of peptide nucleic acids.
Tetrahedron 51, 6179–6194.
Vincze, A., Henderson, R.E.L., McDonald, J.J., Leonard, N.J., 1973. Re-
action of diethyl pyrocarbonate with nucleic acid compounds: bases
and nucleosides derived from guanine, cytosine, and uracil. J. Amer.
Chem. Soc. 95, 2677–2682.
Whitehead, L., Fell, J.T., Collett, J.H., Sharma, H.L., Smith, A., 1998.
Floating dosage forms: an in vivo study demonstrating prolonged gas-
tric retention. J. Control. Release 55, 3–12.
Yalkowsky, S.H., 1999. Solubilization by pH control. In: Solubility and
Solubilization in Aqueous Media. American Chemical Society, Wash-
ington, D.C.
